Reminiscence Therapy-Based Social Group Work for Older Adults in Long-Term Institutional Care
NCT07928414, Not applicable, Not yet recruiting, Melike Türkmen
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Reminiscence Therapy-Based Social Group Work for Older Adults in Long-Term Institutional Care | ClinicalTrials.gov |
| NCT number | NCT07928414 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 44 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Melike Türkmen | ClinicalTrials.gov |
| Conditions | Risk of Mild Cognitive Impairment, Psychological Well-Being, Quality of Life | ClinicalTrials.gov |
| Interventions | Reminiscence Therapy-Based Social Group Work | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Psychological Well-Being Score at Post-Intervention | Baseline (before randomization) and post-intervention (1 to 7 days after the final AT-GSH session; control group assessed during the same calendar week) | Psychological well-being will be assessed using the Turkish version of the eight-item Flourishing Scale (Psychological Well-Being Scale; Diener et al., 2010; Telef, 2013), rated on a 7-point scale. Total scores range from 8 to 56, with higher scores indicating greater psychological well-being. Post-intervention scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The scale is administered by an independent assessor blinded to group allocation. | ClinicalTrials.gov |
| Secondary | Psychological Well-Being Score at 12-Week Follow-Up | Baseline (before randomization) and 12 weeks (plus or minus 1 week) after the final AT-GSH session; control group assessed during the same calendar week | Psychological well-being will be assessed using the Turkish version of the eight-item Flourishing Scale (Psychological Well-Being Scale). Total scores range from 8 to 56, with higher scores indicating greater psychological well-being. Follow-up scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The scale is administered by an independent assessor blinded to group allocation. | ClinicalTrials.gov |
| Secondary | Quality of Life Score at Post-Intervention and 12-Week Follow-Up | Baseline (before randomization), post-intervention (1 to 7 days after the final AT-GSH session), and 12 weeks (plus or minus 1 week) after the final AT-GSH session; control group assessed during the same calendar weeks | Quality of life will be assessed using the Turkish version of the 13-item Older People's Quality of Life Questionnaire-Brief (OPQOL-brief; Bowling et al., 2013; Caliskan et al., 2019), rated on a 5-point scale. Total scores range from 13 to 65, with higher scores indicating better quality of life. Scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The scale is administered by an independent assessor blinded to group allocation. | ClinicalTrials.gov |
| Secondary | Cognitive Status Score at Post-Intervention and 12-Week Follow-Up | Baseline (before randomization), post-intervention (1 to 7 days after the final AT-GSH session), and 12 weeks (plus or minus 1 week) after the final AT-GSH session; control group assessed during the same calendar weeks. | Cognitive status will be assessed using the Turkish version of the Montreal Cognitive Assessment (MoCA-TR; Nasreddine et al., 2005; Selekler et al., 2010). Total scores range from 0 to 30, with higher scores indicating better cognitive performance. Scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The test is administered by the certified researcher delivering the intervention, who is not blinded to group allocation. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)